CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Year-over-year book value per share growth
Latest
-9.77%
↓ 102% vs avg
Percentile
P59
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
532.88%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -9.77% |
| Q3 2025 | -29.94% |
| Q2 2025 | 223.11% |
| Q1 2025 | 5150.47% |
| Q4 2024 | 97.93% |
| Q3 2024 | 25.09% |
| Q2 2024 | 4.74% |
| Q1 2024 | 45.21% |
| Q4 2023 | -11.06% |
| Q3 2023 | 50.34% |
| Q2 2023 | 2.28% |
| Q1 2023 | -1.00% |
| Q4 2022 | -399.72% |
| Q3 2022 | -41.87% |
| Q2 2022 | -28.74% |
| Q1 2022 | 14914.91% |
| Q4 2021 | -100.41% |
| Q3 2021 | -14.02% |
| Q2 2021 | -15.95% |
| Q1 2021 | 1523.20% |
| Q4 2020 | -116.17% |
| Q3 2020 | -18.54% |
| Q2 2020 | -16.29% |
| Q1 2020 | 35.71% |
| Q4 2019 | -37.81% |
| Q3 2019 | -19.24% |
| Q2 2019 | -17.59% |
| Q1 2019 | -6.45% |
| Q4 2018 | -19.11% |
| Q3 2018 | 240.04% |
| Q2 2018 | -17.81% |
| Q1 2018 | -29.43% |
| Q4 2017 | 47.89% |
| Q3 2017 | -13.33% |
| Q2 2017 | -29.67% |
| Q1 2017 | -6.25% |
| Q4 2016 | -12.50% |
| Q3 2016 | -12.14% |
| Q2 2016 | -10.35% |
| Q1 2016 | -10.67% |